ENLV
Enlivex Therapeutics Ltd.
$0.93
+$0.09(+11.11%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$197.83M
Volume
1.43M
52W Range
$0.66 - $2.10
Target Price
$13.00
Company Overview
| Mkt Cap | $197.83M | Price | $0.93 |
| Volume | 1.43M | Change | +11.11% |
| P/E Ratio | -6.8 | Open | $0.86 |
| Revenue | -- | Prev Close | $0.83 |
| Net Income | $-29.1M | 52W Range | $0.66 - $2.10 |
| Div Yield | N/A | Target | $13.00 |
| Overall | 10 | Value | -- |
| Quality | -- | Technical | 10 |
No chart data available
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
Enlivex Shares Tokenized on Ondo Global Markets to Expand Global Digital Investor Access
TipRanks Auto-Generated Newsdesk•11 hours ago
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains
TipRanks Auto-Generated Newsdesk•14 days ago
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback
TipRanks Auto-Generated Newsdesk•15 days ago
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
TipRanks Auto-Generated Newsdesk•16 days ago
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
TipRanks Auto-Generated Newsdesk•16 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENLV | $0.93 | +11.1% | 1.43M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enlivex Therapeutics Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW